Align Technology, Inc. $ALGN Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in Align Technology by 7.1% in Q2, holding 162,704 shares valued at approximately $30.8 million after selling 12,386 shares during the quarter.
• Institutional investors own 88.43% of Align Technology, with significant increases in holdings from firms like Federated Hermes and Mackenzie Financial, reflecting strong institutional interest in the stock.
• Align Technology's CEO, Joseph M. Hogan, bought 7,576 shares at around $131.49 each, totaling approximately $996,168, indicating insider confidence in the company’s future performance.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 7.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 162,704 shares of the medical equipment provider's stock after selling 12,386 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.22% of Align Technology worth $30,805,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of ALGN. Ninety One UK Ltd lifted its holdings in Align Technology by 58.7% in the 1st quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider's stock valued at $307,800,000 after acquiring an additional 716,954 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Align Technology by 510.3% in the 1st quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider's stock valued at $112,396,000 after acquiring an additional 591,588 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Align Technology by 4,217.3% in the 1st quarter. Mackenzie Financial Corp now owns 426,205 shares of the medical equipment provider's stock valued at $67,707,000 after acquiring an additional 416,333 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Align Technology by 94.5% in the 2nd quarter. Nordea Investment Management AB now owns 638,341 shares of the medical equipment provider's stock valued at $121,055,000 after acquiring an additional 310,091 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Align Technology by 104.2% in the 1st quarter. AQR Capital Management LLC now owns 404,310 shares of the medical equipment provider's stock valued at $63,133,000 after acquiring an additional 206,308 shares during the last quarter. 88.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALGN has been the subject of a number of research analyst reports. Morgan Stanley cut their price target on shares of Align Technology from $154.00 to $142.00 and set an "equal weight" rating for the company in a report on Tuesday. Evercore ISI cut their price objective on Align Technology from $170.00 to $160.00 and set an "outperform" rating on the stock in a report on Wednesday, October 8th. Weiss Ratings downgraded Align Technology from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, October 8th. Wells Fargo & Company cut their price objective on Align Technology from $246.00 to $199.00 and set an "overweight" rating on the stock in a report on Thursday, July 31st. Finally, Zacks Research upgraded Align Technology from a "strong sell" rating to a "hold" rating in a report on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $181.67.

Insider Buying and Selling at Align Technology

In other Align Technology news, CEO Joseph M. Hogan bought 7,576 shares of the company's stock in a transaction dated Friday, August 1st. The shares were bought at an average price of $131.49 per share, for a total transaction of $996,168.24. Following the acquisition, the chief executive officer directly owned 184,945 shares of the company's stock, valued at approximately $24,318,418.05. This trade represents a 4.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.66% of the stock is owned by corporate insiders.

Align Technology Price Performance

Shares of ALGN opened at $135.58 on Thursday. The company has a market capitalization of $9.83 billion, a price-to-earnings ratio of 22.86, a P/E/G ratio of 1.54 and a beta of 1.70. Align Technology, Inc. has a fifty-two week low of $122.00 and a fifty-two week high of $246.19. The business's 50-day moving average is $134.43 and its 200-day moving average is $162.85.

Align Technology (NASDAQ:ALGN - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing analysts' consensus estimates of $2.57 by ($0.08). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. Align Technology's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.41 EPS. Align Technology has set its Q3 2025 guidance at EPS. Equities research analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology declared that its Board of Directors has authorized a share repurchase plan on Tuesday, August 5th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.